Ocumetics completes one-month postoperative exams

Executive Summary

• Ocumetics Technology Corp. has completed one-month postoperative examinations for the first patients implanted with the Ocumetics Accommodating Intraocular Lens in Mexico City.
• Clinical results are currently pending analysis, with an update expected shortly.
• The company is proceeding with Group 1 patients under its first-in-human clinical protocol, with additional surgeries scheduled for September 24, 2025.

Key Details

• Procedure Completion: One-month postoperative examinations were performed on Friday, Sept. 12, 2025, for the first cohort of patients implanted on Aug. 15, 2025.
• Clinical Observations: The team observed patient recovery progress and completed visual acuity measurements.
• Next Steps: Patient clinical reports are being analyzed, with a formal update to be provided early in the week following the examinations.
• Study Protocol: The first-in-human clinical protocol addresses three patient groups; the company is currently proceeding with Group 1.
• Upcoming Schedule: Surgeries for the second and final day of Group 1 patients are scheduled for Sept. 24, 2025.
• Primary End Points:
  • Safety: Establishing a clear baseline of patient health and recovery.
  • Distance Vision Correction: Assessing the lens's ability to restore far vision.
• Secondary End Points:
  • Product Handling and Surgical Delivery: Ensuring procedural efficiency and reliability.
  • Near Reading Ability: Evaluating the lens's ability to restore close-range vision.
• Technology Overview: The Ocumetics Accommodating Intraocular Lens fits within the natural lens compartment, designed to allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses.

Notable Quotes

• "On Friday, Sept. 12, we performed one-month postoperative examinations of our first patients implanted with the Ocumetics Lens," said Dean Burns, president and chief executive officer of Ocumetics Technology. "During the examinations we observed progress with recovery and completed a number of visual acuity measurements. Our team will analyze patient clinical reports early this week and provide an update shortly," adds Mr. Burns.